• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4619882)   Today's Articles (912)   Subscriber (49404)
Download
Number Citation Analysis
76
Penault-Llorca F, André F, Sagan C, Lacroix-Triki M, Denoux Y, Verriele V, Jacquemier J, Baranzelli MC, Bibeau F, Antoine M, Lagarde N, Martin AL, Asselain B, Roché H. Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer. J Clin Oncol 2009;27:2809-15. [DOI: 10.1200/jco.2008.18.2808] [Citation(s) in RCA: 191] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]  Open
77
Brain E, Dalenc F, Lokiec F, Dieras V, Bonneterre J, Rezaï K, Mefti-Lacheraf F, Roché H, Jimenez M, Fumoleau P. GEP01: A phase I study of lapatinib (L) and vinorelbine (VNR) in HER2 overexpressing (HER2+) locally advanced or metastatic breast cancer (LAMBC) patients (pts): A FNCLCC Group of early phase trials study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
78
Bertucci F, Le Doussal JM, Birnbaum D, Tagett R, Martinec A, Hermitte F, Marisa L, Martin AL, Geneve J, Roché H, Penault-Llorca F. Prognostic value of the genomic grade index (GGi) as compared to centrally measured Ki-67 IHC and mitotic index in early breast cancer patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.11094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
79
Thivat E, Dalenc F, Durando X, Gladieff L, Mouret-Reynier M, Kwiatkowski F, Deslandres M, Chollet P, Roché H. Treatability of patients with metastatic breast cancer after treatment by ixabepilone in first-line. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e12030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
80
Mancini J, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, Julian Reynier C. Attitudes envers les essais randomisés en cancérologie selon le vécu préalable. Rev Epidemiol Sante Publique 2009. [DOI: 10.1016/j.respe.2009.02.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]  Open
81
Tremollieres F, Frayssinet C, Lèguevague P, Pouillès JM, Rimailho J, Roché H, Soulé-Tholy M, Hoff J, Ribot C. IMPACT OF ADJUVANT HORMONAL THERAPY ON BONE LOSS DEPENDING ON INITIAL ADJUVANT CHEMOTHERAPY AND MENSTRUAL STATUS. Maturitas 2009. [DOI: 10.1016/s0378-5122(09)70094-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
82
Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452-9. [PMID: 19228746 DOI: 10.1158/1078-0432.ccr-08-1080] [Citation(s) in RCA: 476] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
83
Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Breast Cancer Res Treat 2008;116:509-20. [PMID: 19020972 DOI: 10.1007/s10549-008-0250-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2008] [Accepted: 11/07/2008] [Indexed: 01/05/2023]
84
Rugol H, Piontek M, Reeb I, Thomas E, Lee R, Fine L, Peck R, Verrill M, Roché H. Combination therapy with Ixabepilone Plus Capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to Anthracyclines and Taxanes. ACTA ACUST UNITED AC 2008. [DOI: 10.1055/s-0028-1096079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
85
Marino P, Roché H, Biron P, Janvier M, Spaeth D, Fabbro M, Linassier C, Delozier T, Martin AL, Santin G, Moatti JP. Deterioration of quality of life of high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 Quality of Life Study. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2008;11:709-718. [PMID: 18194401 DOI: 10.1111/j.1524-4733.2007.00306.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
86
Berton-Rigaud D, Roché H, Penault-Llorca F, Tubiana-Mathieu N, Ferrero J, Coudert B, Milano GA, Mousseau M, Homokos H, Fumoleau P. Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
87
Dieras V, Viens P, Veyret C, Romieu G, Awada A, Lidbrink E, Bonnefoi H, Mery-Mignard D, Dalenc F, Roché H. Larotaxel (L) in combination with trastuzumab in patients with HER2 + metastatic breast cancer (MBC): Interim analysis of an open phase II label study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.1070] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
88
Mancini J, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, Julian-Reynier C. Décision de participer à un essai clinique en cancérologie: influence du vécu sur les attitudes. ONCOLOGIE 2008. [DOI: 10.1007/s10269-007-0827-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
89
Mancini J, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, Julian Reynier C. Decision-making and breast cancer clinical trialsHow experience challenges attitudes. Contemp Clin Trials 2007;28:684-94. [PMID: 17434812 DOI: 10.1016/j.cct.2007.03.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2006] [Revised: 02/28/2007] [Accepted: 03/04/2007] [Indexed: 11/27/2022]
90
Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol 2007;34:2259-2263. [PMID: 17937464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
91
Jassem J, Thomas E, Gomez H, Li R, Chung H, Fein L, Chan V, Peck R, Mukhopadhyay P, Roché H. 2101 ORAL Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70863-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]  Open
92
Fumoleau P, Llombart-Cussac A, Roché H, Pivot X, Martin M, Kubista E, Verrill M, Conte P. 2119 POSTER Clinical activity of the novel epothilone B analog, ixabepilone, across the breast cancer disease continuum. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70881-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]  Open
93
Julian-Reynier C, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, Maraninchi D. Assessment of Care by Breast Cancer Patients Participating or Not Participating in a Randomized Controlled Trial: A Report With the Patients' Committee for Clinical Trials of the Ligue Nationale Contre le Cancer. J Clin Oncol 2007;25:3038-44. [PMID: 17536083 DOI: 10.1200/jco.2006.08.9367] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
94
Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, Kerbrat P, Delord JP, Vahdat L, Peck R, Lebwohl D, Ezzeddine R, Curé H. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20. [PMID: 17606972 DOI: 10.1200/jco.2006.09.7535] [Citation(s) in RCA: 169] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
95
Puisset F, Alexandre J, Treluyer JM, Raoul V, Roché H, Goldwasser F, Chatelut E. Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 2007;97:290-6. [PMID: 17595656 PMCID: PMC2360335 DOI: 10.1038/sj.bjc.6603872] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
96
Vahdat LT, Thomas E, Li R, Jassem J, Gomez H, Chung H, Peck R, Mukhopadhyay P, Klimovsky J, Roché H. Phase III trial of ixabepilone plus capecitabine compared to capecitabine alone in patients with metastatic breast cancer (MBC) previously treated or resistant to an anthracycline and resistant to taxanes. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1006] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
97
Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Laessig D, Roché H, Zembryki D, Oliva CR, Winer EP. EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy (RT). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1012] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
98
Roché H, Asselain B, Martin AL. In Reply. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.11.0031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
99
Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A, Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer 2007;96:1633-8. [PMID: 17505516 PMCID: PMC2359910 DOI: 10.1038/sj.bjc.6603773] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]  Open
100
Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, Lafont T, Roché H. Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect. Cancer Chemother Pharmacol 2006;60:305-8. [PMID: 17124593 DOI: 10.1007/s00280-006-0385-4] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2006] [Accepted: 10/31/2006] [Indexed: 11/26/2022]
PrevPage 4 of 7 1234567Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA